focus -WSS

focus

author：entertainment 2025-09-30 22:28:38 - browse：68978

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： EU fines Illumina $475 million over Grail acquisition

Wikipedia

entertainment

WSS

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Companies helping big Covid

Young boy dies in trial for Pfizer Duchenne gene therapy

China sends large group of warplanes, navy ships towards Taiwan in forceful display

How are insurers handling Leqembi and related scans?

Companies helping big Covid

hotspot

focus

entertainment

Medical records are filled with copy

Drug companies' payments and gifts affect physicians' prescribing

Hepatitis C has a cure — but many Americans still lack access to it

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Anesthesiologist group: stop taking Ozempic before surgery

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Moonlake's readout produced a cash windfall. Risks remain

Antibody drugs appear effective. Now can we make enough of them?

BioMarin wins approval for gene therapy to treat hemophilia A

Sickle cell gene therapy cures need to be accessible in Africa

focus

Hundreds died while taking an arthritis drug, but nobody alerted patients

Republican states more likely to report Covid vaccine side effects

Vermont grapples with historic flooding as more rainstorms head for Northeast

Companies helping big Covid

Oral obesity drug from Viking Therapeutics hits key early target

Companies helping big Covid

leisure time

Wikipedia

entertainment

leisure time